Literature DB >> 31529493

Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative.

Marius Rademaker1, Karen Agnew2,3, Megan Andrews4, Christopher Baker5,6, Peter Foley5,6, Kurt Gebauer7,8, Monisha Gupta9,10,11, Diana M Rubel12,13, Colin Somerville14, John Sullivan15, Li-Chuen Wong16.   

Abstract

With the rapid development of new, targeted therapies for the treatment of moderate/severe atopic dermatitis, it is opportune to review the available conventional systemic agents. We assess the published evidence for systemic therapies for atopic dermatitis and amalgamate this with real-world experience. Discussions are centred on when systemic therapy should be considered, which drug(s), what dose, how to sequence or combine these therapies, how long they should be continued for and what is considered success.
© 2019 The Australasian College of Dermatologists.

Entities:  

Keywords:  atopic dermatitis; atopic eczema; azathioprine; biologic therapies; ciclosporin; corticosteroids; methotrexate; mycophenolate; second-line therapy; small molecules; systemic treatment

Mesh:

Substances:

Year:  2019        PMID: 31529493     DOI: 10.1111/ajd.13141

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  3 in total

1.  Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.

Authors:  Junqin Liang; Fengxia Hu; Maoli Dan; Yingbing Sang; Kailibinuer Abulikemu; Qian Wang; Yongzhen Hong; Xiaojing Kang
Journal:  Front Immunol       Date:  2022-04-26       Impact factor: 7.561

Review 2.  COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statement.

Authors:  Charlie Wang; Marius Rademaker; Christopher Baker; Peter Foley
Journal:  Australas J Dermatol       Date:  2020-05-03       Impact factor: 2.481

3.  Advice regarding COVID-19 and use of immunomodulators, in patients with severe dermatological diseases.

Authors:  Marius Rademaker; Christopher Baker; Peter Foley; John Sullivan; Charlie Wang
Journal:  Australas J Dermatol       Date:  2020-04-14       Impact factor: 2.875

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.